Guiyang Xintian Pharmaceutical Co Ltd (002873) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.039x

Based on the latest financial reports, Guiyang Xintian Pharmaceutical Co Ltd (002873) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥48.81 Million ≈ $7.14 Million USD) by net assets (CN¥1.26 Billion ≈ $184.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Guiyang Xintian Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Guiyang Xintian Pharmaceutical Co Ltd (002873) financial obligations for a breakdown of total debt and financial obligations.

Guiyang Xintian Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guiyang Xintian Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Career Technology MFG Co Ltd
TW:6153
-0.011x
Vadilal Industries Limited
NSE:VADILALIND
0.174x
Gigastorage Corp
TW:2406
-0.002x
Magna Mining Inc
V:NICU
-0.091x
Nh Investment And Securities 1p
KO:005945
-0.481x
Volcon Inc
NASDAQ:VLCN
-0.265x
Tjk Machinery Tianjin Co Ltd
SHE:300823
0.043x
Ausgold Ltd
AU:AUC
-0.012x

Annual Cash Flow Conversion Efficiency for Guiyang Xintian Pharmaceutical Co Ltd (2012–2024)

The table below shows the annual cash flow conversion efficiency of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Guiyang Xintian Pharmaceutical Co Ltd stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥1.19 Billion
≈ $174.82 Million
CN¥88.13 Million
≈ $12.90 Million
0.074x +5.59%
2023-12-31 CN¥1.11 Billion
≈ $162.92 Million
CN¥77.78 Million
≈ $11.38 Million
0.070x +4.05%
2022-12-31 CN¥1.13 Billion
≈ $165.24 Million
CN¥75.82 Million
≈ $11.09 Million
0.067x -51.90%
2021-12-31 CN¥890.44 Million
≈ $130.30 Million
CN¥124.30 Million
≈ $18.19 Million
0.140x -34.22%
2020-12-31 CN¥828.30 Million
≈ $121.21 Million
CN¥175.77 Million
≈ $25.72 Million
0.212x +345.92%
2019-12-31 CN¥708.76 Million
≈ $103.71 Million
CN¥33.73 Million
≈ $4.94 Million
0.048x -33.95%
2018-12-31 CN¥660.59 Million
≈ $96.66 Million
CN¥47.59 Million
≈ $6.96 Million
0.072x -27.78%
2017-12-31 CN¥622.11 Million
≈ $91.03 Million
CN¥62.06 Million
≈ $9.08 Million
0.100x -54.60%
2016-12-31 CN¥279.21 Million
≈ $40.86 Million
CN¥61.34 Million
≈ $8.98 Million
0.220x +22.08%
2015-12-31 CN¥226.31 Million
≈ $33.12 Million
CN¥40.73 Million
≈ $5.96 Million
0.180x -8.09%
2014-12-31 CN¥190.50 Million
≈ $27.88 Million
CN¥37.30 Million
≈ $5.46 Million
0.196x +122.05%
2013-12-31 CN¥157.38 Million
≈ $23.03 Million
CN¥13.88 Million
≈ $2.03 Million
0.088x -26.49%
2012-12-31 CN¥178.44 Million
≈ $26.11 Million
CN¥21.41 Million
≈ $3.13 Million
0.120x --

About Guiyang Xintian Pharmaceutical Co Ltd

SHE:002873 China Biotechnology
Market Cap
$360.77 Million
CN¥2.47 Billion CNY
Market Cap Rank
#14185 Global
#4460 in China
Share Price
CN¥10.10
Change (1 day)
+2.85%
52-Week Range
CN¥8.85 - CN¥15.19
All Time High
CN¥103738.98
About

Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wine preparation, dews preparations, and two Chinese medicine preparation production lines. Its products are used for the treatment of… Read more